These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 3882058)
1. Double blind trial of bezafibrate in familial hypercholesterolaemia. Wheeler KA; West RJ; Lloyd JK; Barley J Arch Dis Child; 1985 Jan; 60(1):34-7. PubMed ID: 3882058 [TBL] [Abstract][Full Text] [Related]
2. Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia. Curtis LD; Dickson AC; Ling KL; Betteridge J BMJ; 1988 Jul; 297(6642):173-5. PubMed ID: 3044508 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia. Weisweiler P Eur J Clin Pharmacol; 1988; 35(6):579-83. PubMed ID: 3234467 [TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Bradford RH; Goldberg AC; Schonfeld G; Knopp RH Atherosclerosis; 1992 Jan; 92(1):31-40. PubMed ID: 1575820 [TBL] [Abstract][Full Text] [Related]
5. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia. Hailer S; Pogarell O; Keller C; Wolfram G Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936 [TBL] [Abstract][Full Text] [Related]
6. [Effect of bezafibrate therapy on serum and lipoprotein lipids]. Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905 [No Abstract] [Full Text] [Related]
7. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate]. Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481 [TBL] [Abstract][Full Text] [Related]
8. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. Sommariva D; Tirrito M; Bonfiglioli D; Pogliaghi I; Branchi A; Cabrini E Int J Clin Pharmacol Res; 1986; 6(3):249-53. PubMed ID: 3744628 [TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia]. Arntz HR; Bönner G; Kikis D; Kirch W; Klör HU; Lederle RM; Overlack A; Steinmetz A; Stumpe KO Dtsch Med Wochenschr; 1991 Jan; 116(1):7-12. PubMed ID: 1898717 [TBL] [Abstract][Full Text] [Related]
10. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia]. Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892 [No Abstract] [Full Text] [Related]
11. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV]. Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Becker M; Staab D; Von Bergman K Pediatrics; 1992 Jan; 89(1):138-42. PubMed ID: 1727999 [TBL] [Abstract][Full Text] [Related]
13. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]. Noseda G; Fragiacomo C; Weidmann P; Bachmann C Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660 [TBL] [Abstract][Full Text] [Related]
14. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate. Neuman MP; Kurlat MI; Neuman J Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia. Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Betteridge DJ; O'Bryan-Tear CG Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467 [TBL] [Abstract][Full Text] [Related]
17. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Ericsson CG Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064 [TBL] [Abstract][Full Text] [Related]
18. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). de Faire U; Ericsson CG; Hamsten A; Nilsson J Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV]. Sznajderman M Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536 [No Abstract] [Full Text] [Related]
20. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]